Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn Kirkpatrick

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
The Journal of Laboratory and Clinical Medicine|February 7, 2006
The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasmaAmanda F Baker, Tomislav Dragovich, Wendy R Tate, et al.
Cancer Research|January 2, 2009
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistanceNathan T Ihle, Robert Lemos, Peter Wipf, et al.
Organic & Biomolecular Chemistry|July 1, 2004
Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmanninPeter Wipf, Daniel J Minion, Robert J Halter, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2010
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combinationRamesh K Ramanathan, James Abbruzzese, Tomislav Dragovich, et al.
Molecular Cancer Therapeutics|September 20, 2005
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenograftsNathan T Ihle, Gillian Paine-Murrieta, Margareta I Berggren, et al.
Neuro-Oncology|February 17, 2010
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastomaDimpy Koul, Ruijun Shen, Yong-Wan Kim, et al.
Oncology Research|November 24, 2004
In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316Emmanuelle J Meuillet, Nathan Ihle, Amanda F Baker, et al.
Investigational New Drugs|August 25, 2011
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapyRamesh K Ramanathan, Joe J Stephenson, Glen J Weiss, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 1, 2010
Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in miceJörg J Jacoby, Baruch Erez, Maria V Korshunova, et al.
Molecular Cancer Therapeutics|July 15, 2004
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signalingNathan T Ihle, Ryan Williams, Sherry Chow, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
The Journal of Laboratory and Clinical Medicine|February 7, 2006
The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasmaAmanda F Baker, Tomislav Dragovich, Wendy R Tate, et al.
Cancer Research|January 2, 2009
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistanceNathan T Ihle, Robert Lemos, Peter Wipf, et al.
Organic & Biomolecular Chemistry|July 1, 2004
Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmanninPeter Wipf, Daniel J Minion, Robert J Halter, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2010
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combinationRamesh K Ramanathan, James Abbruzzese, Tomislav Dragovich, et al.
Molecular Cancer Therapeutics|September 20, 2005
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenograftsNathan T Ihle, Gillian Paine-Murrieta, Margareta I Berggren, et al.
Neuro-Oncology|February 17, 2010
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastomaDimpy Koul, Ruijun Shen, Yong-Wan Kim, et al.
Oncology Research|November 24, 2004
In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316Emmanuelle J Meuillet, Nathan Ihle, Amanda F Baker, et al.
Investigational New Drugs|August 25, 2011
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapyRamesh K Ramanathan, Joe J Stephenson, Glen J Weiss, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 1, 2010
Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in miceJörg J Jacoby, Baruch Erez, Maria V Korshunova, et al.
Molecular Cancer Therapeutics|July 15, 2004
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signalingNathan T Ihle, Ryan Williams, Sherry Chow, et al.
Pageof 4